Condition
Melas
Total Trials
7
Recruiting
0
Active
0
Completed
4
Success Rate
80.0%-7% vs avg
Key Insights
Highlights
Success Rate
80% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 59/100
Termination Rate
14.3%
1 terminated out of 7 trials
Success Rate
80.0%
-6.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
50%
2 of 4 completed with results
Key Signals
2 with results80% success
Data Visualizations
Phase Distribution
6Total
Not Applicable (1)
P 1 (2)
P 2 (3)
Trial Status
Completed4
Terminated1
Enrolling By Invitation1
Suspended1
Trial Success Rate
80.0%
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (7)
Showing 7 of 7 trials
NCT01803906Enrolling By Invitation
Tissue Sample Study for Mitochondrial Disorders
NCT04846036Phase 2Suspended
The KHENERGYC Study
NCT06051448Phase 1Completed
Promoting Resilience in Stress Management (PRISM) and Clinical-focused Narrative (CFN) Pilot in Adults With Primary Mitochondrial Disease (PMD).
NCT04475549Phase 2TerminatedPrimary
Phase 2a Study of IW-6463 in Adults Diagnosed With Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like Episodes (MELAS)
NCT03432871Not ApplicableCompleted
Nicotinamide Riboside and Mitochondrial Biogenesis
NCT02544217Phase 1CompletedPrimary
A Dose-escalating Clinical Trial With KH176
NCT02909400Phase 2Completed
The KHENERGY Study
Showing all 7 trials